Daniel Hughes

Biography

 founded Resolve in 2010 and has served as its chief executive officer since inception. Prior to founding Resolve, Danywas the chief business officer of GlycoFi, designing the business strategy and executing company transforming partnering deals, including the 2006 sale of the company to Merck. Dany is a scientist by training and has made important contributions to the field of signal transduction through the identification of and cloning of first full length MAP kinase ERK2 and identifying the upstream activating kinase MEK while a postdoctoral fellow at the Fred Hutchinson Cancer Center. Following his postdoctoral training with Jonathan Cooper he was a faculty member at the University of Vermont School of Medicine where he built an NIH-funded basic research group. From academics, Dany pivoted into drug discovery joining Eli Lilly and company where he led multiple drug discovery teams as a member of the biotherapeutics management team.

Research Interest

 founded Resolve in 2010 and has served as its chief executive officer since inception. Prior to founding Resolve, Danywas the chief business officer of GlycoFi, designing the business strategy and executing company transforming partnering deals, including the 2006 sale of the company to Merck. Dany is a scientist by training and has made important contributions to the field of signal transduction through the identification of and cloning of first full length MAP kinase ERK2 and identifying the upstream activating kinase MEK while a postdoctoral fellow at the Fred Hutchinson Cancer Center. Following his postdoctoral training with Jonathan Cooper he was a faculty member at the University of Vermont School of Medicine where he built an NIH-funded basic research group. From academics, Dany pivoted into drug discovery joining Eli Lilly and company where he led multiple drug discovery teams as a member of the biotherapeutics management team.